I think another six months.
The BIT225-010 Phase 2 HIV-1 trial that was run at sites in Thailand included people newly diagnosed as being
HIV-1 positive but not yet commenced ART with BIT225 treatment or placebo continuing for six months in
combination with ART. This extended dosing period allows for a more detailed investigation of immune changes
observed in previously completed HIV-1 clinical studies with BIT225. The endpoints for this trial include
measurements of improved immune function and markers linked to immune reconstitution.
$10 Billion Deal, page-11083
-
- There are more pages in this discussion • 2,304 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BIT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.0¢ |
Change
-0.001(4.76%) |
Mkt cap ! $18.04M | |||
| Open | High | Low | Value | Volume |
| 2.1¢ | 2.1¢ | 2.0¢ | $12.00K | 600.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 972631 | 1.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.1¢ | 199783 | 1 |
View Market Depth
| Last trade - 14.33pm 01/11/2024 (20 minute delay) ? |
| BIT (ASX) Chart |